pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ORKAOruka Therapeutics, Inc.

$ORKA104.86-4.40%
Menlo Park, CA, USupdated 8h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 2: 1
1Phase 2
Phase 2
ORKA-001
Plaque Psoriasis (Psoriasis Vulgaris)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Aug 10, 2026
earnings
$ORKA104.86-4.40%
11d ago
Oruka Therapeutics, Inc. earnings
Oruka Therapeutics, Inc.
→
view all catalysts →

Active trials

  • phase2Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasisactive not recruitingn=160
  • phase2ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasisactive not recruitingn=80
  • phase2An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasisrecruitingn=80
  • phase2Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasisrecruitingn=160
  • phase1ORKA-001 in Healthy Volunteerscompletedn=24
  • phase1ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Doseactive not recruitingn=24

Insider activity

source: SEC Form 4

open-market buys + sells

  • Apr 15, 26SELLGoncalves Joana· Chief Medical Officer4,227 sh @ $65.73−$278K↗
  • Apr 15, 26SELLGoncalves Joana· Chief Medical Officer2,273 sh @ $66.56−$151K↗
  • Apr 15, 26SELLGoncalves Joana· Chief Medical Officer500 sh @ $67.38−$34K↗
  • Mar 16, 26SELLGoncalves Joana· Chief Medical Officer2,902 sh @ $41.20−$120K↗
  • Mar 16, 26SELLGoncalves Joana· Chief Medical Officer2,921 sh @ $40.11−$117K↗
  • Mar 16, 26SELLKlein Lawrence Otto· Chief Executive Officer1,729 sh @ $41.30−$71K↗
  • Mar 16, 26SELLGoncalves Joana· Chief Medical Officer1,177 sh @ $41.94−$49K↗
  • Mar 16, 26SELLQuinlan Paul T· General Counsel733 sh @ $41.30−$30K↗
  • Mar 16, 26SELLGoncalves Joana· Chief Medical Officer641 sh @ $41.30−$26K↗
  • Mar 16, 26SELLSandler Laura Lee· Chief Operating Officer600 sh @ $41.30−$25K↗
  • Mar 16, 26SELLAgarwal Arjun· Senior Vice President, Finance395 sh @ $41.30−$16K↗
  • Mar 2, 26SELLSandler Laura Lee· Chief Operating Officer2,675 sh @ $33.81−$90K↗
  • Mar 2, 26SELLSandler Laura Lee· Chief Operating Officer2,325 sh @ $33.28−$77K↗
routine RSU / option mechanics (6)
  • Apr 15, 26option exerciseGoncalves Joana · Chief Medical Officer3,500 sh
  • Apr 15, 26option exerciseGoncalves Joana · Chief Medical Officer3,500 sh
  • Apr 15, 26option exerciseGoncalves Joana · Chief Medical Officer3,500 sh
  • Apr 15, 26option exerciseGoncalves Joana · Chief Medical Officer3,500 sh
  • Mar 16, 26option exerciseGoncalves Joana · Chief Medical Officer3,500 sh
  • Mar 16, 26option exerciseGoncalves Joana · Chief Medical Officer3,500 sh
🐶 Hiring Signal
No open roles indexed yet — view Oruka Therapeutics, Inc. jobs →

News

  • Oruka surges as long-acting psoriasis drug shows early promise
    A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.
    biopharma_dive · 3mo ago
  • STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study
    A long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a clinical trial, its maker, Oruka Therapeutics, reported.
    stat · 3mo ago
identifiers
ticker
$ORKA
SEC CIK
0000907654
country
US
source
sec_tickers
top tags
Immunology1
mentioned in
2news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 19m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?